TTMI vs CYTK Comparison

TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.